Details for Patent: 8,536,122
✉ Email this page to a colleague
Which drugs does patent 8,536,122 protect, and when does it expire?
Patent 8,536,122 protects OZEMPIC, WEGOVY, and RYBELSUS, and is included in three NDAs.
This patent has forty-two patent family members in twenty-two countries.
Summary for Patent: 8,536,122
| Title: | Acylated GLP-1 compounds |
| Abstract: | Protracted GLP-1 compounds and therapeutic uses thereof. |
| Inventor(s): | Lau; Jesper (Farum, DK), Doerwald; Florencio Zaragoza (Smorum, DK), Bloch; Paw (Taastrup, DK), Hansen; Thomas Kruse (Herlev, DK) |
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Application Number: | 13/412,283 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,536,122 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,536,122
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-004 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-003 | Mar 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,536,122
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 05102171 | Mar 18, 2005 | |
International Family Members for US Patent 8,536,122
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1863839 | ⤷ Sign Up | 300936 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1863839 | ⤷ Sign Up | 2018C/016 | Belgium | ⤷ Sign Up |
| European Patent Office | 1863839 | ⤷ Sign Up | CR 2018 00019 | Denmark | ⤷ Sign Up |
| European Patent Office | 1863839 | ⤷ Sign Up | 122018000075 | Germany | ⤷ Sign Up |
| European Patent Office | 1863839 | ⤷ Sign Up | 2018/017 | Ireland | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
